Correspondence 0001477932-24-006336 from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Date: Oct. 10, 2024 · CIK: 0001187953 · Accession: 0001477932-24-006336
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282512
Letter
Via Edgar Division of Corporation Finance Office of Life Sciences Registration Statement on Form S-3 Filed October 4, 2024 File No. 333-282512 Request for Acceleration
Dear Ms. Gama:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Creative Medical Technology Holdings, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement to 4:00 p.m. on Tuesday, October 15, 2024, or as soon thereafter as practicable.
Please contact Zev M. Bomrind of Pachulski Stang Ziehl & Jones LLP, counsel to the Company, at (646) 483-5497, as soon as the registration statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Sincerely,
/s/ Timothy Warbington
Show Raw Text
CORRESP 1 filename1.htm celz_corresp.htmCreative Medical Technology Holdings, Inc. 211 E Osborn Road Phoenix, Arizona 85012 October 10, 2024 Via Edgar Ms. Doris Stacey Gama Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission Washington, D.C. 20549 Re: Creative Medical Technology Holdings, Inc. Registration Statement on Form S-3 Filed October 4, 2024 File No. 333-282512 Request for Acceleration Dear Ms. Gama: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Creative Medical Technology Holdings, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement to 4:00 p.m. on Tuesday, October 15, 2024, or as soon thereafter as practicable. Please contact Zev M. Bomrind of Pachulski Stang Ziehl & Jones LLP, counsel to the Company, at (646) 483-5497, as soon as the registration statement has been declared effective, or if you have any other questions or concerns regarding this matter. Sincerely, /s/ Timothy Warbington Timothy Warbington Chief Executive Officer